Life sciences focused fund has executed three investments to date

New York, 16th April 2019: SWORD Health, a tech-enabled physical therapy provider, has raised $8 million in a series A investment round led by Khosla Ventures and several other prominent angel investors. It will allow SWORD to focus on bringing its technology to more patients' homes and expand its footprint in the U.S. market. The investment will bring SWORD Health closer to its ultimate goal of cutting the costs of Musculoskeletal Disorders (MSDs) in the U.S. by half. The funding round will also allow the company to further expand the product's clinical validation and engineering.

Mecuris GmbH, a Munich-based medical technology start-up focusing on the digitization of prostheses and orthoses, has won Denise Schindler as its brand ambassador. The Paralympic cyclist and current Vice World Champion will be the face of Mecuris for the next four years. Through this cooperation, both partners want to advance the digitalization of orthopedic technology and create public awareness that self-confident handling of a prosthesis is possible.

Turku, Finland, March 7th 2019: Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women's health, today announces that it has successfully completed Phase 1a study of its lead program FOR-6219, a novel, tissue specific treatment of endometriosis. FOR-6219 was found to be safe and well tolerated, with good pharmacokinetics at the doses tested.

Mecuris GmbH, a commercial-stage Munich-based medical technology startup focusing on the digitalization of prosthetics and orthotics, successfully completes its Series-A financing round of EUR 3.6m. In addition to existing seed investors Bayern Kapital and High-Tech Gründerfonds (HTGF), the new investors Vesalius Biocapital, Mulcan International Investments and one of the Top 5 hospital chains in Germany support now the innovative Mecuris approach.

Turku, Finland, September 5th 2018: Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women's health, today announces that it has raised an additional €4 million of funding from Vesalius Biocapital III Partners (Vesalius III). This is in addition to the €12 million Series A financing in 2014 and €5,7 million R&D loans granted by Business Finland since 2014. Vesalius III joins the existing international investor syndicate comprising Novo Seeds, Karolinska Development, Novartis Venture Fund, M Ventures and Innovestor. Stéphane Verdood, Managing Partner from Vesalius III, joins Forendo Pharma's Board of Directors.

PORTO, 16 April 2018: SWORD Health, the creator of the AI-powered digital physiotherapist SWORD Phoenix, announces the close of its $4.6 million seed funding round. The investment, provided by Vesalius Biocapital III, Locapes and other undisclosed investors, will be used to accelerate the development of new digital therapies and drive SWORD Health's global growth.

First international investment by IFD
New fund will focus on investing in Portuguese life science companies

Luxembourg-Bertrange, 18 May 2017 – Vesalius Biocapital, the specialist life sciences venture capital investor, announces the first close of its third fund, Vesalius Biocapital III, securing over €65 million of commitments as at 15 May 2017. Until the final closing in 2018, Vesalius Biocapital III will accept new investors on a "rolling closing" basis.